Full review
Noah AI CAIHL draft report
Evidence-linked HugoScore draft report for a health AI tool that affects patients.
Agency checklist · October 30, 2026
Mixed 6 of 12 yes
Document-based draft. Independent confirmation is incomplete. Hugo has not personally verified this service.
Assessed function: Noah X, the publicly accessible Noah AI professional research agent, assessed for a patient's direct research use. Hypothetical downstream pharma-industry effects are not scored.
A no can mean missing documentation or institution-dependent control; it does not by itself establish harmful behavior. These categories are not clinical safety or product-quality ratings.
- Public documents do not establish actual product behavior.
- The independent review screened rules and selected evidence; it did not replicate all twelve answers for this tool.
See all twelve answers and their evidence
| Question | Answer | Evidence / review | Source and reasoning |
|---|---|---|---|
| 1. Told it is AI | Yes | documented Not independently replicated | Meet Noah X, an AI agent built for the way you work.Source The privacy notice also says the Services include products 'powered by artificial intelligence'. |
| 2. Operator and model maker named | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source TOLONGEVITY PTE. LTD. (dba Noah AI) is named as operator. No model maker is named for Noah X, and the pages describe the 'Noah World Model' without saying whether third-party LLMs are used. |
| 3. Patient chooses to use it | Yes | documented Not independently replicated | Try Noah X for FreeSource A user registers and chooses to use it. The product targets individual professionals and enterprises, so a patient using it is off-label. |
| 4. Patient sets the task | Yes | documented Not independently replicated | Ask it yourself. A biomedical generalist for your daily work, from discovery through commercial.Source The user sets the question for this research agent. |
| 5. Patient can decline or stop | Yes | documented Not independently replicated | Try Noah X for FreeSource Self-started tool per the Q3 source, no care depends on it. |
| 6. Patient sees the AI output | Yes | documented Not independently replicated | Trace every claim to its filing, trial, paper, or patent in one click.Source The user sees cited answers to their own questions. The output is research content, not an output about the patient. |
| 7. Patient can correct or challenge | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source The policy lists a right to correct inaccuracies in personal data, conditional on residence. No route to contest Noah X output. |
| 8. Patient can get a copy | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source The notice says users 'may have the right' to a copy depending on state or region, by emailing [email protected]. No general export is documented. |
| 9. Patient can delete | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Section 17 gives an email route to delete personal information, but only 'based on the applicable laws of your country or state'. I treated a jurisdiction-conditional legal right as not documented. |
| 10. Training or sale does not override patient choice | Yes | documented Not independently replicated | Your prompts, data and outputs never train anything of ours.Source This is the home page Trust & provenance claim. The privacy notice says only that Noah may use data 'for undertaking internal research for technological development and demonstration' and has an unspecific AI opt-out in account settings. The privacy notice does not contradict the home claim but does not repeat it. |
| 11. Patient can run it or take it elsewhere | No | not-documented Not independently replicated | Quotation not recorded; evidence repair pending. Source Vendor-hosted only. Enterprise deployments run models in the customer's environment, which does not apply to individual users. |
| 12. No advertising or data business | No | documented Not independently replicated | We also permit third parties and service providers to use online tracking technologies on our Services for analytics and advertisingSource The privacy notice also lists Ad Networks, Retargeting Platforms and Affiliate Marketing Programs among third-party categories. It says no personal information was sold or shared in the last 12 months. |
Initial coding: Claude Sonnet helpers, compiled by Claude Opus 5.5 (Anthropic). Selective review and corrections: GPT-6 Astra (OpenAI). Editor: Hugo Campos. Acceptance of corrections is not product verification.
Checklist rules · Independent review and limitations · Later evidence follow-up
Earlier report
Noah AI: CAIHL reassessment
September 8, 2026. Published AI-assisted draft.
Noah AI supports direct research questions, scope clarification, and editable evidence. These patient-accessible functions must be distinguished from inferred institutional uses. The evidence does not establish universal absence of recourse or dominant downstream effects.
Scope and agency posture
Publicly accessible professional research agent. Evaluate a patient's direct research use separately from hypothetical downstream industry effects. Preserve August 13 baseline 55 and its corrected prior-model history.
Posture: Mixed.
Axis: 55/100, retained provisionally. No numerical recalibration was performed.
Sources and documented findings
- The current homepage describes scope and constraint clarification, cited research, editable workflows and downloadable underlying data. Its use cases and testimonials emphasize life-science professionals. It lists GPT, Gemini, Claude and Grok and offers a support/feedback route. These establish product orientation, not the prevalence or consequences of industry use.
- The current privacy policy still states that sensitive information is not processed, names advertising/retargeting categories, describes general AI processing and an opt-out, and allows deletion or anonymization after retention needs end. It does not explain the specific health-query and downstream-model conditions well enough to resolve the prior gap.
- The current terms exclude uses subject to HIPAA and other named sector rules. That is a service restriction, not proof that an individual consumer's question is prohibited or that patient data is sent to advertisers.
Patient authority
Inference from the documented workflow: In direct use, patients can define research goals and constraints and take editable evidence away. Professional market positioning does not erase that authority. Patients affected by another organization's analysis are a different deployment and cannot be assigned a blanket lack of recourse without evidence.
Critical capacity
Editorial assessment: Citations and downloadable interim analysis can help users challenge framing and conclusions. The baseline's assertion that nothing supports patient action is too absolute: research can support a patient's chosen action without a dedicated appointment or appeal feature.
Informed control
Editorial assessment: The policy remains poorly specific about sensitive research inputs and model recipients. Distinguish documented advertising categories from an unsupported claim that health prompts are disclosed to them. Search absence cannot confirm that independent evidence does not exist.
Assessment and limits
Retain a mixed assessment but remove assertions about its largest real-world patient effect, universal lack of notice/recourse and confirmed absence of evidence. These exceed a public-source review. Center actual patient goal-setting and evidence export alongside unresolved conditions.
Confidence: Low to medium, primary documents only.
Remaining uncertainty: Direct patient experience, clinical boundaries inside the app, processor terms, research-input use and actual institutional deployments remain unknown.
Published documentation is evidence of stated conditions, not proof of actual implementation. Unknowns did not receive automatic negative points. Funding, sponsorship, and public code do not determine agency by themselves.
Review provenance
- Reviewer/model: OpenAI Codex / GPT-6.
- Method: Focused public-source reassessment using CAIHL: patient authority, critical capacity, and informed control. Existing evidence plus one focused primary-source pass and at most one targeted follow-up. No live product testing. Numerical scores remain provisional editorial placements, not a new calculation.
- Human review: Hugo Campos authorized publication of these AI-assisted draft reassessments on September 8, 2026. This does not claim comprehensive human verification of every finding.
- Earlier review: 2026-08-13. Historical assessment. Earlier claims are not automatically reverified by this publication.